Resalis Therapeutics announced that it has closed a €10 million ($11 million) funding round, the Series A round that follows the seed round of the same value that took place at the end of 2022. The transaction is led by Sunstone Life Science Ventures and is attended by existing investors, including Claris Ventures and angel investors. The new funds will be used to initiate and complete the first Phase 1 clinical trial in humans and to reach Phase 2 of the core Resalis program that identifies RES-010 in obesity. RES-010 is a non-coding RNA-based compound designed to provide a disease-modifying approach in obesity with longer-lasting weight reduction and the ability to extend treatment duration in combination with approved drugs, such as GLP-1 receptor agonists. “The success of the Series A round is an important milestone for Resalis, as it will allow us to reach the clinical stage and reach the next major inflection point with our lead candidate, RES-010. With RES-010 we aim to provide a therapy that precisely reduces fat mass in obesity with the potential to extend the duration of existing therapies. We appreciate the trust and support of our new and existing investors and look forward to this next phase of development,” Alessandro Toniolo, CEO of Resalis Therapeutics, said in a statement Resalis’ therapeutic approach is based on innovative science that has rapidly led to the development of a lead candidate, which is now in development and in the process of being clinically evaluated.” Preservation of muscle mass is critical to providing a lasting and meaningful clinical benefit, and we share the team’s view that this non-GLP1/GIP drug will significantly improve both the effect and tolerability of current therapies. “This investment underscores our confidence in the company’s vision and “The potential to transform its lead candidate to have a significant impact on obese patients,” said Claus Andersson, general partner at Sunstone Life Science Ventures, who joins the Board of Directors of Resalis following the round. Pietro Puglisi, managing partner of Claris Ventures and Chairman of the Board of Directors of Resalis Therapeutics, adds: “Significant progress has been made in the treatment of metabolic disorders in recent years, however, there is still a critical need for innovative solutions that can both provide orthogonal therapeutic effects and pave the way for combination therapies. I look forward to continuing to collaborate with the outstanding team at Resalis and welcoming Claus as a new member of the Resalis Board of Directors.”
Fighting obesity
Resalis has a deep understanding of the field of ncRNAs and RNA-targeted therapies in human health and metabolic disorders. The Company’s lead candidate, RES-010, is an oligonucleotide antisense oligonucleotide that targets miR-22, a central player in the regulation of lipid metabolism and energy consumption. In multiple proof-of-concept studies in large and small animal models, RES-010 has been shown to provide an effective answer to the problem of lipid metabolism. Resalis plans to initiate a Phase 1 clinical trial to evaluate the safety and efficacy of RES-010 in the first half of 2024. RES-010 is patent-protected in the United States, Japan, and China, and patent-pending in the EU. (Photo by i yunmai on Unsplash)
ALL RIGHTS RESERVED ©